Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C60H72N8O6 |
Molecular Weight | 1001.2637 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@H](N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@@]1([H])CCCC2)C3=NC4=CC=C(C=C4N3)C5=CC6=CC=C5CCC7=CC=C(CC6)C(=C7)C8=CC=C9N=C(NC9=C8)[C@@H]%10C[C@]%11([H])CCCC[C@]%11([H])N%10C(=O)[C@@H](NC(=O)OC)C(C)C
InChI
InChIKey=LSYBRGMTRKJATA-IVEWBXRVSA-N
InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1
Odalasvir (previously known as ACH-3102) is a second-generation inhibitor of the nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It was reported that HCV NS5A is associated with interferon signaling related to HCV replication and hepatocarcinogenesis. HCV NS5A inhibitors efficiently inhibited HCV replication. It is known that HCV is a leading cause of hepatocellular carcinoma (HCC) in Japan and is one of the major causes of end-stage liver disease, HCC, and liver transplantation in the United States and Europe. Odalasvir completed phase II clinical trial, where was evaluated efficacy and safety of its combinations with AL-335, and simeprevir in the treatment of chronic hepatitis C Infection.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. | 2018 Dec |
|
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. | 2018 Jun |
|
Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. | 2018 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02765490
Odalasvir 25 mg tablet will be administered once daily.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71474517
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
CD-120
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
SUB179997
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
100000166047
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
9924
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
OVR52K7BDW
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
DB13041
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
C174815
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL3544977
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
ACH-3102
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
DTXSID401032258
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY | |||
|
1415119-52-6
Created by
admin on Sat Dec 16 09:45:15 GMT 2023 , Edited by admin on Sat Dec 16 09:45:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)